TL;DR — Humanin was the first mitochondrial-derived peptideA short chain of amino acids — smaller than a full protein — that usually acts on a specific cell-surface receptor rather than a broad metabolic pathway. Full glossary → discovered, with cytoprotective and anti-apoptotic effects in cell and mouse models, characterized substantially by Pinchas Cohen's group. Human evidence here is genuinely different in kind from most peptides on this list: real observational studies correlate circulating humanin levels with age and disease — but that's association, not intervention. No trial has given people exogenous humanin and measured an outcome.
What Humanin is — the first mitochondrial-derived peptide discovered
Humanin was the first identified member of the "mitochondrial-derived peptide" (MDP) class — short peptides encoded within mitochondrial DNA rather than the nuclear genome — originally discovered in the early 2000s in the context of Alzheimer's disease research, where it was found to protect neurons from Alzheimer's-disease-related cell death in culture. Pinchas Cohen's group (also central to MOTS-c's discovery) has done much of the subsequent characterization work on its broader biology.
Circulating humanin levels have been studied observationally in humans: several published studies report correlations between humanin levels and age, and between humanin levels and specific conditions (including cardiovascular disease and cognitive decline markers). This is a genuinely different evidence category from most peptides on this list — real human data exists, but it's correlational, not interventional.
Primary hallmarks targeted: Mitochondrial dysfunction · Cellular senescence
Cohen and colleagues, along with the original discovery groups, report humanin has cytoprotective and anti-apoptotic effects in cultured human and mouse cells, and separately report observational human studies correlating circulating humanin levels with age and with specific disease states (cardiovascular, cognitive). No published trial has administered exogenous humanin to humans and measured a clinical or biomarker outcome.
Mechanism — cytoprotection and anti-apoptotic signaling in cell/mouse models
| Reported effect | Study type | Hallmark link |
|---|---|---|
| Neuroprotection against Alzheimer's-related cell death | Cell culture | Cellular senescence |
| Anti-apoptotic signaling broadly | Cell culture, mouse models | Mitochondrial dysfunction |
| Circulating levels correlate inversely with age | Human observational studies | Mitochondrial dysfunction |
| Circulating levels correlate with cardiovascular/cognitive markers | Human observational studies | Cellular senescence |
The observational human data is worth taking seriously as a research signal — it's a real, if indirect, line of evidence that humanin biology matters in human aging. But it answers a different question than "does giving someone more humanin help." Correlational studies can't distinguish whether low humanin is a cause of age-related decline, a consequence of it, or a marker of some third factor — and only an interventional trial can resolve that.
Why observational correlation can't justify a dosing protocol
If declining humanin were purely causal in age-related decline, restoring it might help. If it's a downstream marker of some other process, restoring it artificially would do nothing. The human data available cannot distinguish between these — which is exactly why no dosing protocol can be responsibly derived from it yet.
Evidence summary
| Study type | Model | Key reported outcome | Tier |
|---|---|---|---|
| Original discovery studies | Human neuron cell culture | Neuroprotection against Alzheimer's-related toxicity | C |
| Cohen et al. and related groups | Mouse, cell culture | Anti-apoptotic, cytoprotective signaling | C |
| Human observational cohort studies | Human, correlational | Circulating levels correlate with age/disease | C (observational, not interventional) |
| Human interventional trial | — | None published | — |
← Swipe for more columns →
What can the human observational data actually justify?
Are you looking for evidence that raising humanin levels changes an outcome?
That evidence does not exist yet — only correlation between natural levels and outcomes has been studied, not intervention.
The observational data is a legitimate research signal worth watching, but not a basis for a personal dosing decision today.
No human dosing, safety, or pharmacokinetic data exists for exogenous humanin administration at any dose.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Practical use — why observational data cannot justify a dosing protocol
Because no interventional human trial exists, there is no independently established human dose, safety profile, or expected effect size for exogenous humanin administration. What circulates in research-chemical communities extrapolates dosing from mouse studies, the same imprecise translation method used for MOTS-c and epithalon, with the same attendant uncertainty.
This is observational-evidence-only, not preclinical-intervention evidence
- No interventional data at all — even the "C tier" here rests on correlation and cell/mouse mechanism, with zero human dosing studies, a step below peptides that at least have animal intervention data.
- No human safety data — nothing to reference for expected side effects or risks.
- Unregulated sourcing — same research-chemical vendor risks as other peptides on this list.
Safety, red flags, and contraindications
- No human safety data exists at any dose — there is no reference point for expected adverse effects.
- Avoid during pregnancy or breastfeeding.
- No characterized interaction profile exists with any medication or other peptide.
- Given the total absence of human dosing data, treat any use as genuinely exploratory rather than protocol-following.
Personal tracking template
My Humanin tracking log
| Date | Week | Subjective cognitive/energy marker (0–10) | Notes |
|---|---|---|---|
| YYYY-MM-DD | 0 | — | Baseline before any use |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Any tracked change should be treated cautiously given the complete absence of human interventional data to compare against. - No effect: No change in tracked markers. - Stop and reassess: Any unexplained symptom, given zero human safety reference data.
Explore mitochondrial-health levers with human intervention data
Compare against compounds with actual human interventional trials for the same hallmark.
Open the Mitochondrial Dysfunction Hallmark